Insights on switching from Invega Sustenna to UZEDY for schizophrenia treatment are revealed by new data.
Teva Pharmaceuticals in the United States, a branch of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has revealed the unveiling of seven studies on its extended-release injection technology.